The San Francisco Board of Supervisors will vote Tuesday on a resolution urging Mayor Daniel Lurie to implement a “comprehensive” strategy to dismantle The City’s open-air drug markets and expand ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Patients who struggle with opioid addiction and who are treated by California emergency department physicians are remarkably ...

Researchers are investigating whether a common cholesterol drug could be repurposed to treat HPV-positive cervical cancer.

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Philadelphia would cut business tax rates every year and begin spending hundreds of millions of newly allocated dollars on ...

A key federal agency responsible for addiction and mental health services is facing deep staff cuts.

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

Meiragtx's AAV-GAD program for Parkinson's disease is phase 3 ready, with positive data from a randomized, sham-controlled ...

ST. PAUL, Minn. - The Minnesota Department of Human Services (DHS) is trying to ease concerns as a drug treatment provider ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...